Cell cycle checkpoints and DNA repair act in concert to ensure DNA integrity during perturbation of normal replication or in response to genotoxic agents. Deficiencies in these protective mechanisms can lead to cellular transformation and ultimately tumorigenesis. Here we focused on Rev3, the catalytic subunit of the low-fidelity DNA repair polymerase f. Rev3 is believed to play a role in double-strand break (DSB)-induced DNA repair by homologous recombination. In line with this hypothesis, we show the accumulation of chromatin-bound Rev3 protein in late S-G2 of untreated cells and in response to clastogenic DNA damage as well as an c-H2AX accumulation in Rev3-depleted cells. Moreover, serine 995 of Rev3 is in vitro phosphorylated by the DSB-inducible checkpoint kinase, Chk2. Our data also disclose a significant reduction of rev3 gene expression in 74 colon carcinomas when compared to the normal adjacent tissues. This reduced expression is independent of the carcinoma stages, suggesting that the downregulation of rev3 might have occurred early during tumorigenesis.
Introduction
Normal cells duplicate their genome with high fidelity. Intrinsic replication failures, cellular metabolites or exogenous agents may cause mutations that could ultimately give rise to tumor development (Ishikawa et al., 2006) . Thus, normal cells have evolved two main groups of protective pathways that are able to deal with different types of DNA damage accumulating during their life span, that is cell cycle control and DNA repair pathways, which constitute the DNA damage response (DDR). Specific checkpoints control cell cycle progression to give enough time for the cell to repair damaged DNA or alternatively to induce a process of senescence or apoptosis (Melo and Toczyski, 2002; Laiho and Latonen, 2003) . During this cell cycle arrest, DNA is repaired by specific pathways (Slupphaug et al., 2003) .
Clinical observations have shown that at early stages of human tumorigenesis, cells are characterized by genome instability and DDR deficiency (Gorgoulis et al., 2005; Bartkova et al., 2006; Bartek et al., 2007) . Therefore, a two-step mechanism has been proposed to explain tumor initiation. First, DNA-damage accumulation due to unbalanced DNA replication timing, oncogene introduction or DNA-repair defects triggers the activation of DDR, which in turn blocks cell cycle progression. The second step is a loss of DDR controls, leading to cell cycle resumption with genome-instability propagation (Gorgoulis et al., 2005; Bartkova et al., 2006; Bartek et al., 2007) .
One of the most deleterious initial damages that can affect genome stability and thus contribute to induce cellular transformation is the double-strand break (DSB). Detection and repair of DSBs are thus essential aspects of tumor suppression. The mode of DSBinduced repair varies according to the phase of the cell cycle (Liang et al., 1998) . Non-homologous end joining is believed to play a main role in DSB-dependent repair in G1 phase (Liang et al., 1998) . In contrast, in G2 or at the end of S phase, where replication fork failure causes the accumulation of DSB, homologous recombination (HR)-dependent repair is taking over (Liang et al., 1998; Lisby et al., 2003) . Indeed, faithful HR requires duplication of the genome and implicates that the ends of a DSB are resected to expose single-stranded DNA, which is used to search for homology in the sister chromatid (Liang et al., 1998; Lisby et al., 2003) . A candidate for such resection was recently characterized in human cells as the CtlP protein linked with the MRN11 complex (Sartori et al., 2007) . Nevertheless, studies in yeast have demonstrated that the HRdependent repair process is not a conservative repair as might be expected, but has a higher mutagenic rate than normal replication (Strathern et al., 1995; Rattray and Strathern, 2003) , as it could involve low-fidelity DNA polymerases such as polymerase Z (McIlwraith et al., 2005) or polymerase z (Pol z) Zhu and Zhang, 2003; Barbour et al., 2006) .
Pol z is composed of three subunits, co-associated Rev3 and Rev7 and one independent co-factor Rev1 (Rattray and Strathern, 2003) , which are all conserved from yeast to man Zhu and Zhang, 2003) . Rev3 is the catalytic subunit, whereas Rev7 is required for full activity of Pol z in vivo Zhu and Zhang, 2003) . Rev1 is a common factor of several polymerases (Guo et al., 2003) . The key properties distinguishing Pol z from other high-fidelity polymerases such as Pol a, d and e are its ability to copy severely damaged DNA and to extend mispaired primers (Nelson et al., 1996; Johnson et al., 1998 ; reviewed by Zhu and Zhang, 2003) . Thus, Pol z was included in the translesions synthesis (TLS) polymerases family group. Interestingly, reports in yeast suggest genetic and biochemical links between pol z subunits and DDR elements (Kai and Wang, 2003) . In metazoans, rev3-deficient cells are also sensitive to DSB inducers, accumulate p53 spontaneously and harbor a high frequency of chromatid breaks due to an HR-dependent DNA-repair defect (Van Sloun et al., 2002; Sonoda et al., 2003) . Embryonic lethality of rev3-deficient mice could thus be due to its implication in DSB repair, although one cannot completely exclude its participation in other essential aspects of cell cycle metabolism (Van Sloun et al., 2002; Sonoda et al., 2003) .
Finally, several reports revealed a strong interrelation between the HR-dependent DNA repair processes and DDR in mammals (Ishikawa et al., 2006) . In particular, two ATM/ATR downstream checkpoint effector kinases, Chk1 and Chk2 (Ishikawa et al., 2006) , are both coordinators of HR-dependent repair. Chk1 regulates Rad51B function (Sorensen et al., 2005) whereas Chk2, which is specifically activated in response to DSB, phosphorylates three other HR-dependent DNA repair proteins: BRCA1, the endonuclease Mus81/EMI1 and FoxM1, a transcription factor regulating DNA repair gene expression (Boddy et al., 2000; Blais et al., 2004; Zhang et al., 2004; Tan et al., 2007) .
Here, we focused on human Rev3 expression during the cell cycle and in response to DNA-damaging agents. We show that Rev3 can be phosphorylated in vitro by the DSB checkpoint kinase, Chk2. We observe that Rev3 depletion leads to genome instability by DSB accumulation and that the rev3 gene has a lower expression in tumor versus normal tissues from early to late stages of colon carcinoma. Altogether, our findings provide new evidences for a role of Rev3 as tumor suppressor and suggest new interconnections between DNA repair and DDR-pathway deficiencies during early stages of tumor progression.
Results
Human Rev3 protein exclusion from chromatin in early S phase Rev3 protein expression levels have not been determined in mammalian cells yet. Indeed, Rev3 is a very large protein with a theoretical molecular weight of 375 kDa. As we were not able to detect full-length Rev3 protein by western blot experiments, we tried to determine the expression and the localization of Rev3 in human cells by indirect immunofluorescence using a newly available polyclonal antibody (SC-5939 from Santa Cruz, Santa Cruz, CA, USA). Immunodetection was performed on Triton X-100-permeabilized cells as previously described (Brondello et al., 2007) to detect only the chromatin bound and active fraction of Rev3. As shown in Figure 1a and Supplementary Figure S1 , a nuclear staining of varying intensity was detected with the Rev3 antibody in proliferating U2OS osteosarcoma cells or in normal human mesenchymal stem cells, suggesting a cell cycle-dependent chromatin binding of Rev3. The specificity of the staining was validated by its reduction in Rev3 small interfering RNA (siRNA)-transfected cells.
To determine a putative link between DNA replication and Rev3 chromatin association, we used an immunodetectable base analog, bromodeoxyuridine (BrdU), as DNA replication marker. BrdU was added to the cell culture 60 min before fixation. Simultaneous staining with anti-BrdU to detect replicating cells and anti-Rev3 antibodies was then performed. As shown in Figure 1b , 57.4% ( ± 6.89) of BrdU-negative cells revealed a high signal for Rev3 compared with only 39.6% (±3.42) of BrdU-positive cells. This observation suggests that Rev3 association with chromatin is reduced in replicating cells. To confirm this hypothesis, we synchronized U2OS cells at the G1/S boundary by hydroxyurea addition and released them into fresh medium (Figure 1c ). Cell cycle progression was then followed by DNA-content analysis at different time points. In parallel, Rev3 staining was performed as described. As shown in Figure 1c , cells at the G1/S boundary (time 0) have higher levels of Rev3, which decreased after progression through S phase and re-appeared 6-9 h after release, at the end of S phase and in G2. Interestingly, in the same experiment, Rev3 mRNA levels remained constant (data not shown).
Altogether, these variations in the triton-insoluble fraction of Rev3 protein during cell cycle progression are in favor of a variation of the chromatin binding of Rev3 during the cell cycle and/or a posttranscriptional regulation of its expression.
DNA damage-dependent accumulation of human Rev3 mRNA and protein Previous studies in metazoans have shown that the rev3 gene is transcriptionally induced following DNA damage (for review see Zhu and Zhang, 2003) . We wanted to verify whether human Rev3 and its associated subunit Rev7 mRNAs are induced upon DNA damage in our cellular system. Thus, U2OS cells were mock-treated or treated with a clinically used radiomimetic agent, bleomycin (BL, 1.5 mU/ml), for 4 h. Rev3 and Rev7 mRNA levels were quantified by quantitative PCR after normalization to 28S rRNA levels. Rev3 mRNA is induced 1.78-fold (±0.28) in response to BL compared with mock-treated cells (Figure 2a ). In contrast, Rev7 mRNA levels do not increase significantly after treatment. These data confirm previous published results showing a transcriptional regulation of Rev3 in response to DNA damage (Rattray and Strathern, 2003; Zhu and Zhang, 2003) .
To assess whether chromatin-bound Rev3 protein levels increase in parallel with Rev3 mRNA levels in response to DNA-damaging agents, we detected Rev3 protein by indirect immunofluorescence in cells challenged with BL as described above. Cells were mock-treated or treated with BL for 4 h and then analysed for Rev3 and g-H2AX expression. g-H2AX is an ATM-dependent phosphorylated form of H2AX that is commonly used as marker of the presence of DNA damage (Burma et al., 2001) . Mocktreated cells have low detectable level of g-H2AX with fluctuating levels of Rev3 protein ( Figure 2b ). In contrast, in the presence of BL, 92% ( ± 4.22) of analysed cells displayed a concomitant accumulation of Rev3 and g-H2AX. These observations show that the chromatinbound Rev3 protein accumulation occurs in DNAdamaged cells.
In vitro phosphorylation of Rev3 serine 995 by Chk2
There is more and more evidence that cells have evolved interconnections between DDR and DNA repair. As already mentioned, not only Chk2-deficient cells but also cells deficient in ATM, the direct upstream activator of Chk2, are hypersensitive to DSB-inducing agents (Yamamoto et al., 2006; Bindra et al., 2007) . Biochemical experiments have revealed that this sensitivity is not only due to a defect in cell cycle arrest but also due to a defect in HR-dependent DNA repair processes Yamamoto et al., 2006; Bindra et al., 2007) . Moreover, Pol z, and especially Rev3, is transcriptionally regulated in response to DSB inducers and possesses some DSB repair functions (Hochegger et al., 2004) . Thus, we raised the hypothesis that Rev3 functions could also be directly regulated by the DDR pathway. Interestingly, analysis of the human Rev3 protein sequence revealed the presence of a putative phosphorylation site for Chk2 kinase at position 995 (O'Neill et al., 2002) . This sequence is conserved in all analysed Rev3 orthologs ( Figure 3a) .
We next investigated whether a fragment of Rev3 containing this putative phosphorylation site could be an in vitro substrate for Chk2. We performed an in vitro kinase assay with Chk2, immunoprecipitated from mock-treated or BL-treated cells, and used as substrate Rev3 downregulation in colon carcinomas J-M Brondello et al a purified recombinant fragment of Rev3 (aa 900-1041) fused to gluthation-S-transferase. As shown in Figure 3b , the activated form of Chk2 obtained from damaged cell extracts is able to incorporate higher 32 phosphate levels into the wild-type GST-Rev3 fragment than background levels in the presence of g-32 P-ATP. Next, we wanted to verify whether the Chk2-dependent phosphorylation of the Rev3 N-terminal fragment requires the serine residue found at position 995 in the consensus site (Figure 3a) . Thus, serine 995 was mutated into an alanine residue. A similar in vitro kinase assay was performed. As expected, phosphorylation levels of the Ala 995 mutant fragment were strongly reduced with respect to the wild-type fragment and equivalent to background levels ( Figure 3c ). This result shows that activated Chk2 can phosphorylate serine 995 of Rev3 in vitro.
g-H2AX accumulation in Rev3-deficient cells As described for rev3 yeast mutants, rev3-deficient cells in metazoans displayed increased sensitivity to a variety of DNA-damage inducers such as ultraviolet, methyl methanesulfonate or g-irradiation (Van Sloun et al., 2002; Sonoda et al., 2003) . Furthermore, rev3 deletion induces an HR-dependent DNA repair defect and the spontaneous accumulation of p53 (Van Sloun et al., 2002) . These phenotypes are compatible with a role of Rev3 in the repair by HR of spontaneously accumulated DNA damage during cellular life span, especially at the end of S phase and in G2 (Figure 1) . According to this model, Rev3 ablation should promote an accumulation of spontaneously induced DSB in proliferating cells, even in the absence of genotoxic agents. To test this hypothesis in human cells, we took advantage of siRNAs targeting specifically Rev3 to reduce its expression levels in vivo. As shown in Figure 4a , transfection of Rev3 siRNAs in U2OS cells dramatically reduced the levels of Rev3 mRNA compared with mock-transfected cells (64%±3.21). In Rev3-depleted cells, Rev7 mRNA is slightly induced, suggesting the existence of a cross talk between the two genes.
We next analysed the impact of Rev3 depletion on the presence of DSB in U2OS cells. The g-H2AX marker was then used to follow the presence of spontaneous DSB in Rev3-depleted cells compared with mocktreated cells by indirect immunofluorescence (Burma et al., 2001) . As shown in Figure 4b 
Rev3 gene downregulation in colon carcinomas
To assess the expression of Rev3 in human tumors, we have quantified the levels of transcripts displayed by non-tumoral/tumoral coupled biopsies extracted from 74 patients suffering from colorectal carcinoma and who had not received any therapy before or past surgery. Figure 5 indicates that although the expression of the replicative pol d remained unchanged (as well as pol e, not shown), the T/N ratio of Rev3 was significantly lower than 1 (Po10 À4 ) in tumors compared with adjacent tissues. The percentage of tumors that displayed a more than twofold downregulation of the rev3 gene was 54.06% (T/No2 in 40/74 biopsies). To test whether a twofold change in gene expression was relevant, we realized a bilateral exact binomial test as described in Supplementary Information. This led us to conclude that Rev3 expression is reduced from stages I to IV of colorectal adenocarcinomas.
Discussion
In response to replication perturbation or DNA-damage accumulation, DDR is activated to prevent cell cycle progression and allow repair of the damage. DDR is thus believed to be an important defense against cellular transformation. Indeed, clinical evidences demonstrate that DDR is activated during early stages of tumorigenesis and that further tumor progression requires the inactivation of essential elements of the DDR such as p53 or Chk2 (Bartkova et al., 2005 (Bartkova et al., , 2006 Gorgoulis et al., 2005; Bartek et al., 2007) . Therefore, to understand how initial DNA-damage accumulation can be induced at early stages of tumor progression is an important objective. Recent work proposed that Rev3, a catalytic subunit of Pol z, is linked to DDR in budding yeast (Sabbioneda et al., 2005; Barbour et al., 2006) . Indeed, Rev3 has recently been shown to physically interact with Rad9, Rad1 and Hus1, which are three proliferating cell nuclear antigen-like DDR sensor proteins (Sabbioneda et al., 2005) . Furthermore, in metazoans, rev3-deficient cells display genomic instability, which is a fundamental characteristic of cancer cells (Van Sloun et al., 2002; Sonoda et al., 2003) . Here, we bring additional evidence in favor of the regulation of Rev3 by DDR in mammalian cells and we propose that Rev3 could function as a tumor suppressor in colon carcinomas.
We first showed a slight increase in Rev3 mRNA levels in response to a DSB inducer, confirming that Rev3 gene expression is regulated in response to cellular stress (Figure 3a ) (Zhu and Zhang, 2003) . In the future, it will be important to determine whether this stimulation is due to Rev3 mRNA stabilization or rather due to the consequence of a transcriptional regulation via DNA-damage responsive elements in the rev3 promoter.
We then followed the levels of Rev3 protein by indirect immunofluorescence of triton-permeabilized cells (Figures 1 and 2) . We could show chromatinbound Rev3 protein accumulation in response to DNA damage (Figure 3) . Interestingly, in untreated cells, we detected Rev3 mainly at the S-G2 transition and in the G1 phase of the cell cycle. Another subunit of Pol z, Rev1, has recently been shown to have a quite similar cell cycle-restricted expression pattern at the end of S phase and in G2. Furthermore, it has been recently observed that inappropriate expression in human cells of two other TLS polymerases, Pol k and b, could lead to the accumulation of mutations by competition with the high-fidelity polymerases, which normally replicate DNA during S phase (Canitrot et al., 2004; Bavoux et al., 2005) . We propose that Pol z activity, like that of other TLS polymerases, has to be tightly regulated during the cell cycle to prevent accumulation of mutations. This could happen by the regulation of Rev1 expression and Rev3 chromatin binding.
We also observe an accumulation of DSB in Rev3-depleted cells (Figure 4 ). Rev3 mutant cells harbor a high frequency of chromatid breaks, most likely due to an accumulation of unrepaired DNA damage, as observed for other mutants of proteins involved in DSB repair by HR (Hochegger et al., 2004) . Remarkably, Rev3 appears to be unique among TLS family members, as other TLS polymerase mutants exhibit, on the contrary, an elevated frequency of sister chromatid exchange (Hochegger et al., 2004) . Thus, DSB accumulation in the absence of Rev3 activity could be simply explained by HR-dependent repair deficiency of naturally occurring DSB (Hochegger et al., 2004) , although we cannot completely rule out that the absence of Rev3 itself could be responsible for the creation of DSB.
In higher eukaryotes, HR occurs mainly at the end of DNA replication and in G2 (Liang et al., 1998) . HR is a multistep process that involves the recognition of the DSBs, strand invasion, Holliday junction formation and its resolution (Bindra et al., 2007) . Remarkably, we observed that Rev3 protein accumulates in cell cycle phases in which HR occurs predominantly. Thus Pol z Rev3 downregulation in colon carcinomas J-M Brondello et al could participate in HR by using its capability to elongate DNA from mismatched templates and thus helping Holliday junction formation, particularly between two homologous chromosomes (Rattray and Strathern, 2005) . Furthermore, we identified here Rev3 as a new in vitro substrate for Chk2 kinase (Figure 3) , one of the key regulators of HR-dependent repair. Indeed, as already mentioned, HR-dependent repair was the first DNA repair process described as directly coordinated by the DDR. Several repair proteins involved in HR such as H2AX, BRCA1, Rad51 and Mus81/EME1 are regulated by DDR, and more particularly by Chk2 Tan et al., 2007) . Although in vivo phosphorylation of Rev3 on serine 995 needs to be demonstrated, it is likely that Chk2 could directly regulate Rev3 activity during HRdependent repair, for instance through inducing its association with chromatin. Thus, DDR would be able after DSB-dependent activation to coordinate all steps of DSB repair from initial recognition of the lesion to Holliday junction formation and resolution.
Eukaryotic cells have a large number of specialized translesion DNA polymerases to cope with genomic lesions, including Pol z (Rattray and Strathern, 2003) . Genetic analyses in yeast and mammals have revealed a crucial role for these TLS polymerases for survival under genotoxic stress and their regulation by DDR (Liu et al., 1999; Kai and Wang, 2003; Rattray and Strathern, 2003) . Furthermore, depletion of Rev3 induces p53 accumulation and ATM-dependent phosphorylation of H2AX (Figure 4 ) (Van Sloun et al., 2002; Sonoda et al., 2003) . Similar observations were made in the initial stages of different tumors (Bartkova et al., 2005 (Bartkova et al., , 2006 Gorgoulis et al., 2005; Bartek et al., 2007) . Remarkably, we found that Rev3 gene expression is reduced by at least twofold in 54.06% of analysed coupled human colon tumor samples independently of tumor grade. A lower expression of Rev3 was also reported in prostate cancer (Lapointe et al., 2004) . Thus, Rev3 downregulation could be one of the earliest events in the progression of colon cancer. Moreover, such event could procure a selective advantage in the course of the neoplasia. It could lead to the appearance of DNA damage and the activation of DDR. Further loss of this DDR could be required for the progression to cellular transformation and tumorigenesis.
Altogether, our findings strongly argue that the Pol z subunit Rev3 plays a crucial role not only during embryonic development and stress responses but also in the prevention of colon cancer (Zhu and Zhang, 2003) .
Materials and methods
Cell culture conditions, synchronization, materials and drugs U2OS cells (American Type Culture Collection) and human mesenchymal stem cells (gift from Dr C Jorgensen) were cultivated in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum, 50 U/ml penicillin and 50 mg/ml streptomycin sulfate. Cells were treated for 4 h with BL (5 mU/ml) (Calbiochem, San Diego, CA, USA). For cell cycle synchronization, cells were treated for 24 h with 2 mM of hydroxyurea (SigmaAldrich, St Louis, MO, USA) and released from hydroxyurea block as previously described (Brondello et al., 2007) . G2/M cells were obtained by a 24 h treatment with 10 mg/ml of nocodazole (Sigma-Aldrich). Proper cell cycle progression was monitored by DNA-content analysis using an fluorescenceactivated cell sorting counter (Becton-Dickinson, Franklin Lakes, NJ, USA). Triton X-100 and Nodinet P-40 (Pierce, Rockford, IL, USA). The enhanced chemiluminescence immunodetection system was obtained from Amersham (Piscataway, NJ, USA). 
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Construction of expression vectors and in vitro mutagenesis of Rev3 cDNA
The full-length human Rev3 cDNA (a gift from Professor Lawrence CW, University of Rochester School of Medicine and Dentistry, NY, USA) was used as template to amplify by PCR a fragment (940-1040 of Rev3) with the primers CCGCGGATCCTCCCCTGCAACCAAATA and CCGGC TCGAGTTATATGGGACTTGTGC. The PCR product was subcloned into the pGEX-4T2 expression vector (Stratagene, Santa Clara, CA, USA). Mutation of the consensus Serine 995 site was performed using a quick-change site-directed mutagenesis kit of Stratagene using the primer 'CTTTGGCT TTCAGGAAAAAACGGTCACATGCTA'. The BL21-DE3 strain was transformed with each vector. Glutathione-Stransferase fusion proteins were produced and purified using gluthation sepharose beads as described by Stratagene.
Real-time quantitative PCR analysis RNA extraction was performed as described (Chomczynski and Sacchi, 2006) . RNA integrity was checked by agarose gel electrophoresis. cDNA synthesis was performed with 1 mg of DNase-treated total RNA using 200 U of SuperScript II RNaseH reverse transcriptase (Invitrogen) and 250 ng of random hexamers according to the manufacturer's instructions. Quantitative PCR was performed on a 7000 SDS instrument (Applied Biosystems, Foster City, CA, USA) using SyberGreen PCR MasterMix (Applied Biosystems) and the primers CTTTCATGTTCTTCATCAGCGTTTT and CCAC GGACACGGCTAACATAA for Rev3 and TCCACTGC TGTCCATCAGCTC and GCACACGCTGATCTTCAGGA for Rev7. The PCR was performed in a final volume of 15 ml, with 7.5 pmol of primers and an amount of cDNA corresponding to 6.5 ng of total RNA. Rev3 PCR primers were designed to detect all Rev3 alternatively spliced mRNAs (7770-7892). For each set of primers, a standard curve was plotted with serial dilutions of cDNA or DNA template to evaluate the efficiency of the amplification. A melting curve was systematically performed to check for specific amplifications. mRNA expression was normalized to 28S rRNA as endogenous reference.
siRNA transfection and immunofluorescence For siRNA transfection, U2OS cells (2 Â 10 5 per 3.5 cm plate) were transfected with an oligofectamine agent according to the manufacturer's protocol (Invitrogen) with either b-galactosidase siRNA control (Invitrogen) or siRNA against Rev3 (UrCUrGrGrCrGrCUrGUrCrArArGUUCTT). Two rounds of transfection were necessary. For immunodetection, cells were grown on coverslips, treated as described in the figure legends, permeabilized or not with 0.5% triton and fixed as previously described (Todorov et al., 1995) . Immunodetection of Rev3 was performed using anti-Rev3 (SC-5939 from Santa Cruz) revealed with anti-goat antibody conjugated with Alexa 548 (Molecular Probes, Carlsbad, CA, USA). g-H2AX and BrdU were detected using a previously described protocol (Burma et al., 2001 ) and monoclonal antibodies JBW103 from Cell signaling (Franklin Lakes, NJ, USA) and anti-BrdU from Becton-Dickinson, respectively. DNA was stained with Hoechst 33258 (Sigma-Aldrich).
Preparation of cell extracts, immunoprecipitation and western blot analysis Cells were washed twice with cold phosphate-buffered saline and lysed in buffer A (25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-KOH (pH 7.5), 100 mM NaCl, 40 mM KCl, 20 mM MgCl 2 , 50mM NaF, 5 mM ethylene glycol tetraacetic acid, 40 mM b-glycerophosphate, 200 mM sodium orthovanadate, 10 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mM pepstatin A and 1% Nonidet P-40) for 15 min at 4 1C. Insoluble material was removed by centrifugation at 12 000 g for 2 min at 4 1C. After protein-concentration determination, proteins from cell lysates (30 mg) were separated by 15% SDS-polyacrylamide gel electrophoresis. After transfer on nitrocellulose, the blots were incubated with anti-actin (1:5000, Sigma) or anti-g-H2AX (1:100) antibodies and revealed with horseradish peroxidase-conjugated protein AG (1:5000).
In vitro phosphorylation of Rev3 fragment by activated Chk2 U2OS cells were mock-treated or treated for 5 h with 1.5 mU/ml of BL. Cells were washed with ice-cold phosphate-buffered saline and lysed in lysis buffer A for 15 min at 4 1C. Insoluble material was removed by centrifugation at 12 000 g for 5 min at 4 1C. A total of 500 mg of total proteins from cell lysates were incubated with anti-Chk2 antibody (Anaspec Inc., San Jose, CA, USA), preabsorbed to protein A-Sepharose-coated beads for 2 h at 4 1C. Immune complexes were washed three times with buffer A and mixed with the beads coated with purified GST-Rev3 (940-1040) (WT or S/A995). After mixing, the beads were washed again with kinase buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4), 20 mM MgCl, 1 mM MnCl). Chk2 activity was finally assayed by resuspending the final pellet in 50 ml of kinase buffer containing 5 mCi [g T/N values lower than 1 were transformed to the inverse value N/T. The symbols þ and À indicate that expression is higher or lower, respectively, in the tumor versus adjacent control tissue. Black boxes above the x axis indicate the sample numbers. P-values from bilateral exact binomial test are given uncorrected, the significance level is evaluated using the procedure by Benjamini, Krieger and Yekutieli for an overall FDR of 0.05. FDR, false discovery rate. of Laemmli sample buffer and then heated at 95 1C for 5 min. Proteins were separated by SDS-polyacrylamide gel electrophoresis (12.5%), and the gels were subjected to autoradiography.
Tissue specimen, RNA extraction and PCR analysis Tissue specimens from 74 patients who underwent surgery for primary colorectal adenocarcinoma resection at the Toulouse University Hospital between 1999 and 2002 were selected. RNA extraction, PCR amplification and quantification were performed as described in Supplementary Information and Lemee et al. (2007) .
